Skip to content

Efficacy of Yellow Cassava to Improve Vitamin A Status of Kenyan School Children

Efficacy of Yellow Cassava to Improve Vitamin A Status of Mildly Deficient Primary School Children in Kenya: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01614483
Acronym
CASSAVITA
Enrollment
341
Registered
2012-06-08
Start date
2012-05-31
Completion date
2012-11-30
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin A Deficiency

Keywords

Vitamin A deficiency, Biofortification, Cassava, B-carotene, School children, Kenya

Brief summary

The overall aim of the project is to provide proof-of-principle that biofortification of cassava with vitamin A is a viable strategy to improve vitamin A status of deficient populations.

Detailed description

Rationale: Vitamin A deficiency is still common in developing countries and has been proven difficult to combat. A promising approach is to replace common crops with varieties that are naturally richer in vitamin A, which is referred to as biofortification. For cassava, yellow β-carotene rich varieties have recently been introduced in Kenya, and these varieties are now ready to be tested for their efficacy to improve vitamin A status in humans. Objective: The primary objective is to measure the effect of daily consumption of provitamin A biofortified cassava (providing 50% of the age-specific RDA) on vitamin A status in children aged 5-13 years with mild to moderate vitamin A deficiency in Kenya. To determine the bioefficacy of provitamin A carotenoids from biofortified cassava relative to that of a daily B-carotene supplement (comparison with positive control group). Secondary objectives are: 1) to measure the effect of the intervention on immune function indicators and morbidity; 2) to determine to what degree the serum retinol response to the intervention depends on serum concentrations of retinol and zinc at baseline; 3) to determine the effect of the intervention on functional indicators such as dark adaptation capacity, gut integrity, hematology indicators and thyroid status; 4) to determine the mediating effect of SNP's in the BCMO1 gene on treatment outcome. Study design & Study population : In this randomized controlled trial, school children aged 5-13 years living in the Kibwezi area, Kenya. Children will be selected from three (or four) primary schools in the area that have been pre-selected based on the prevalence of vitamin A deficiency, location and willingness to participate. Intervention: After screening for eligibility and a 2-week run-in period (n=360) Children will be randomly allocated to three different treatments: 1) 400 g of yellow cassava providing \ 50% of the RDA for vitamin A; and a placebo capsule; 2) 400 g of white cassava; and a placebo capsule; 3) 400 g of white cassava and a capsule containing 100 RAE of all-trans β-carotene. Main study parameters/endpoints: The main outcome measure will be differences in serum retinol concentrations between groups. Other outcome measures include other vitamin A status indicators (β-carotene, retinol binding protein, transthyretin), immune function indicators, dark adaptation, iron status indicators, anthropometrics, gut integrity, and thyroid function.

Interventions

OTHERYellow cassava

Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week

Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week

Sponsors

European Commission
CollaboratorOTHER
University of Nairobi
CollaboratorOTHER
Wageningen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
61 Months to 13 Years
Healthy volunteers
Yes

Inclusion criteria

* Low vitamin A status (retinol binding protein (RBP) at the lowest end of the distribution will be included in the study)

Exclusion criteria

* History or signs of infectious or systemic diseases (e.g. tuberculosis, sickle cell anaemia) * Anaemia, malaria or acute inflammation at the day of baseline measurements

Design outcomes

Primary

MeasureTime frame
Change in serum retinol concentrationBaseline, end of study (4 months)

Secondary

MeasureTime frameDescription
BioefficacyBaseline, end of study (4 months)Comparison of change in serum retinol between yellow cassava group and positive control (B-carotene supplement group)
Functional indicatorsEnd of study (4 months)Gut integrity, dark adaptation, morbidity
Immune function indicatorsEnd of study (4 months)neopterin, IL-2, IL4, IL10, IL13, TNF-a, IFN-γ, TGF-β in serum; IgA in saliva
Effect modificationBaselineSerum zinc, serum retinol, iron status, polymorphisms
AnemiaEnd of study (4 months)Hemoglobin
Thyroid functionEnd of study (4 monthsSerum Tg, TSH

Countries

Kenya

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026